Therapists in the near future could be giving clients MDMA and psychedelics

MDMA
Sam Woolfe

The US Food & Drug Administration (FDA) has designated MDMA (‘ecstasy’) a ‘breakthrough drug’ for the treatment of post-traumatic stress disorder (PTSD). The Multidisciplinary Association for Psychedelic Studies (MAPS) now has the green light to design two upcoming Phase 3 trials of MDMA-assisted psychotherapy for patients with severe PTSD.

A promising treatment

The FDA grants Breakthrough Therapy Designation to a drug:

  1. intended alone or in combination with one or more other drugs to treat a serious or life-threatening disease or condition, and:
  2. preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.

MDMA has been given this status because it could offer relief for PTSD sufferers for whom no other treatment has worked. Tony Macie, a retired US army sergeant, participated in initial trials. As he wrote in a 2014 Reddit ‘Ask Me Anything’ thread:

Start your day with The Canary News Digest

Fresh and fearless; get excellent independent journalism from The Canary, delivered straight to your inbox every morning.

After about an hour of just relaxing and being in the present is when memories started to come up. For me if I tried to push them away I would feel anxious, but if I dealt with it and processed the memory, I would have a wave of pleasure come over my body. I believe that the MDMA was showing me how to deal with my trauma and also that it is more beneficial for me to face trauma head on than to try and ignore it or suppress it. I had a lot of powerful [realizations] that day.

How MDMA may benefit PTSD sufferers

PTSD is difficult to treat because its symptoms can include:

intense or prolonged psychological distress at exposure to internal or external cues that symbolize or resemble an aspect of the traumatic events.

Revisiting the traumatic memory can be deeply unsettling. So sufferers will avoid reminders of the trauma; which, as Macie points out, acts as a roadblock to relief.

MDMA’s therapeutic potential rests in its ability to:

  • Increase oxytocin levels, which could strengthen the bond between the therapist and client.
  • Decrease amygdala activity, which reduces fear and anxiety, and may improve emotional regulation and decrease avoidance.

It has been difficult to assess whether MDMA is neurotoxic. Although a randomised controlled pilot study found no adverse changes in the brain when subjects with PTSD took MDMA.

Future medicine

In 2015, Rick Doblin (founder of MAPS – which sponsors research into the therapeutic potential of cannabis, MDMA and psychedelics) said:

We’re on track for MDMA to be approved by the FDA by 2021.

He also anticipated that, by late 2017, MAPS would reach an agreement with the FDA on the design of Phase 3 trials. And his prediction was correct. So in four years’ time, it may be unsurprising to find therapists using MDMA therapy for PTSD. The drug could also end up being used for couples therapy, as well as other anxiety conditions, or conditions influenced by trauma (e.g. depression).

The therapeutic potential of psychedelics

In addition, we may see psychedelics legalised for medicinal purposes around the same time. Research has show that magic mushrooms, for example, can lift depression and end-of-life anxiety. As The Canary previously reported, creating a legal and regulated environment in which psychedelics can be taken is better for safety and efficacy.

Mark Haden, Executive Director of MAPS Canada, says that medicinal magic mushrooms may be used legally in the near future. A second study into the effects of magic mushrooms on depression is at the same stage as these MDMA trials. He said it’s the “same timeline”, adding:

When we finish our phase three study, we submit our data to Health Canada… and they look at it and say ‘we approve.’

One problem (among many) of the War on Drugs is that it slows down research into the potential benefits of these substances; which is a shame, as study participants and users will stress that they can catalyse the healing process. MDMA and psychedelics seem to allow individuals with mental health and relationship issues to approach and address their problems in ways that traditional methods of treatment struggle to do.

Get Involved!

– Check out more articles from The Canary on drug policy.

– Support MAPS.

Featured image via Wikimedia

Since you're here ...

We know you don't need a lecture. You wouldn't be here if you didn't care.
Now, more than ever, we need your help to challenge the rightwing press and hold power to account. Please help us survive and thrive.

The Canary Support

Comments are closed